Market Overview

UPDATE: Stifel Nicolaus Initiates Covidien at Hold on Pending Spin-Off

Related COV
Covidien Conference Call Highlights
US Stock Futures Surge Ahead Of Earnings, ADP Data
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

Stifel Nicolaus initiated coverage on Covidien (NYSE: COV) with a Hold rating.

Stifel Nicolaus said, "In our view, there is very little one can find in the Covidien story that is not to like. Since the company's spin-off from Tyco five years ago, Covidien has set clear financial and operating goals and delivered on them with accelerating organic growth in its key business lines and significant gross margin expansion. Looking ahead, we think COV is poised for continued growth above its large-cap MedTech peers. However, a reasonable valuation and the potential for incremental pharma spin-off related dilution keep us on the sidelines."

Covidien closed at $56.17 on Monday.

Latest Ratings for COV

DateFirmActionFromTo
Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqualweight
Jul 2014CitigroupMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (COV)

Around the Web, We're Loving...

Get Benzinga's Newsletters